Company Overview and News
Gladstone Commercial Corporation (GOOD - Free Report) recently shelled out $8.3 million for the acquisition of an industrial building in Delaware, OH. The move is in sync with the company’s efforts to strengthen its allocation to industrial buildings and particularly boost presence in the target market of Columbus. The 157,810-square-foot industrial building is fully occupied by a designer and manufacturer of thermal and acoustical engineering products — Midwest Acoust-A-Fiber.
GOODM GOODN PLD DRE GOOD LPT GOODO GOODP TITN
Duke Realty Corp. (DRE - Free Report) is experiencing solid demand for properties in Turnpike Crossing industrial park. The company stated that Turnpike Crossing 6729 — a 146,253-square feet industrial building that was delivered on Sep 1 — has been 75% leased. Eastern Metal Supplies, a distributor and fabricator of aluminum extrusions and sheet products, has leased 109,523 square feet in the property.
PLD DRE TRNO LPT
Terreno Realty Corporation (TRNO - Free Report) recently shelled out approximately $22.8 million for the purchase of an industrial property in San Leandro, CA. This acquisition comes as part of the company’s concerted efforts to capitalize on robust fundamentals of the industrial real estate sector through purchase of potential properties in core markets. Built on 7.3 acres of land, the property consists of three industrial distribution buildings containing 128,000 square feet of space.
PLD DRE TRNO UNP LPT
One of the biggest misconceptions in investing has to do with real estate investment trusts (REITs) and rising interest rates. As a high-yielding security — thanks to their tax structures — dividend-hungry people often look for REITs to buy to pad their portfolios. However, common wisdom is that investors tend to dump shares of REITs as the Federal Reserve raises rates. After all, when rates are higher you can get bigger yields from “safer” securities like treasury bonds.
UPS FDX WFM AMZN DEI PLD EQR SPG KIM AVB
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to PLD / Prologis, Inc. on message board site Silicon Investor.
|PLDI (Nasdaq)- Petersburg Long Distance||PLDI (Nasdaq)- Petersburg Long Distance||PLDI (Nasdaq)- Petersburg Long Distance|
as of ET